Andrew Tsai
Stock Analyst at Jefferies
(2.91)
# 1,433
Out of 5,140 analysts
28
Total ratings
45.83%
Success rate
1.54%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Andrew Tsai
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AXSM Axsome Therapeutics | Maintains: Buy | $200 → $245 | $183.72 | +33.36% | 2 | Feb 3, 2026 | |
| DFTX Definium Therapeutics | Initiates: Buy | $30 | $17.13 | +75.13% | 1 | Jan 30, 2026 | |
| VTGN Vistagen Therapeutics | Downgrades: Hold | $15 → $0.9 | $0.56 | +60.97% | 3 | Dec 17, 2025 | |
| MRNA Moderna | Initiates: Hold | $30 | $49.87 | -39.84% | 1 | Dec 12, 2025 | |
| PRAX Praxis Precision Medicines | Maintains: Buy | $300 → $450 | $335.28 | +34.22% | 2 | Dec 9, 2025 | |
| MPLT MapLight Therapeutics | Initiates: Buy | $32 | $17.88 | +78.97% | 1 | Nov 21, 2025 | |
| ANRO Alto Neuroscience | Maintains: Buy | $15 → $25 | $17.62 | +41.88% | 2 | Nov 12, 2025 | |
| BIIB Biogen | Initiates: Buy | $190 | $192.03 | -1.06% | 1 | Sep 25, 2025 | |
| SRPT Sarepta Therapeutics | Maintains: Buy | $40 → $35 | $18.88 | +85.38% | 3 | Jul 24, 2025 | |
| STOK Stoke Therapeutics | Initiates: Buy | $30 | $34.29 | -12.51% | 1 | Jul 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $70 | $68.14 | +2.73% | 1 | Jul 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $29 → $2.5 | $3.78 | -33.86% | 2 | May 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $19 → $27 | $17.27 | +56.34% | 2 | Mar 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $3.5 → $13 | $4.13 | +214.77% | 2 | Sep 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $35 | $29.76 | +17.61% | 1 | Jul 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Hold | $3 | $1.47 | +104.08% | 1 | Mar 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $27 | $3.88 | +595.88% | 1 | Sep 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $16 → $23 | $42.23 | -45.54% | 1 | Jun 1, 2020 |
Axsome Therapeutics
Feb 3, 2026
Maintains: Buy
Price Target: $200 → $245
Current: $183.72
Upside: +33.36%
Definium Therapeutics
Jan 30, 2026
Initiates: Buy
Price Target: $30
Current: $17.13
Upside: +75.13%
Vistagen Therapeutics
Dec 17, 2025
Downgrades: Hold
Price Target: $15 → $0.9
Current: $0.56
Upside: +60.97%
Moderna
Dec 12, 2025
Initiates: Hold
Price Target: $30
Current: $49.87
Upside: -39.84%
Praxis Precision Medicines
Dec 9, 2025
Maintains: Buy
Price Target: $300 → $450
Current: $335.28
Upside: +34.22%
MapLight Therapeutics
Nov 21, 2025
Initiates: Buy
Price Target: $32
Current: $17.88
Upside: +78.97%
Alto Neuroscience
Nov 12, 2025
Maintains: Buy
Price Target: $15 → $25
Current: $17.62
Upside: +41.88%
Biogen
Sep 25, 2025
Initiates: Buy
Price Target: $190
Current: $192.03
Upside: -1.06%
Sarepta Therapeutics
Jul 24, 2025
Maintains: Buy
Price Target: $40 → $35
Current: $18.88
Upside: +85.38%
Stoke Therapeutics
Jul 18, 2025
Initiates: Buy
Price Target: $30
Current: $34.29
Upside: -12.51%
Jul 14, 2025
Initiates: Buy
Price Target: $70
Current: $68.14
Upside: +2.73%
May 28, 2025
Downgrades: Hold
Price Target: $29 → $2.5
Current: $3.78
Upside: -33.86%
Mar 19, 2025
Maintains: Overweight
Price Target: $19 → $27
Current: $17.27
Upside: +56.34%
Sep 17, 2024
Upgrades: Buy
Price Target: $3.5 → $13
Current: $4.13
Upside: +214.77%
Jul 2, 2024
Initiates: Buy
Price Target: $35
Current: $29.76
Upside: +17.61%
Mar 7, 2023
Initiates: Hold
Price Target: $3
Current: $1.47
Upside: +104.08%
Sep 1, 2021
Initiates: Buy
Price Target: $27
Current: $3.88
Upside: +595.88%
Jun 1, 2020
Assumes: Buy
Price Target: $16 → $23
Current: $42.23
Upside: -45.54%